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Mean (SEM) Naive Sham Injected Acute Arthritis MOR Rx Acute Arthritis MOR Alone CAP Pre-treatment CAP Alone Day 6
EPS 0.87 (0.41) 1.67 (0.88) 6.57 (1.01) 0.67 (0.42) 1.88 (0.85) 3.2 (0.58) 1.67 (1.67)
DWB (L/R) % Weight 102.6 (2.47) 96.3 (8.56) 83.7 (5.26) 98.4 (6.35) 96.2 (1.95) 106.4 (7.96) 104.1 (10.59)
DWB (L/R)% Time on Limb 100.6 (0.97) 100.0 (1.60) 94.7 (2.16) 99.9 (0.59) 99.2 (0.80) 99.07(1.98) 101.1 (1.91)
Results (Values in bold and italics p<.05)
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S270(0.15mg/knee). Some mice were injected IA with CAP (0.305 mmol)
7 days before induction of arthritis. DWBwasmeasured with a Dynamic
Weight Bearing apparatus (Bioseb, Vitrolles, France). Evoked pain scores
were derived by tallying ﬁghts + vocalizations/1 minwith repeated ﬁrm
palpation of the knee. Substance P signal intensity from ipsilateral and
contralateral DRGs in the lumbar region were compared by immuno-
histochemistry. Development of inﬂammatory arthritis was conﬁrmed
by histology.
Results: Arthritis pain was clearly and reproducibly indicated by
increased EPS in arthritic mice. DWB was signiﬁcantly reduced by
acute arthritis in the affected limb measured by both % weight bearing
and time on the affected limb. IA MOR improved EPS and DWB by all
measures. Pretreatment with capsaicin abolished the increased EPS
from carrageenan arthritis and normalized DWB by all measures. IA
CAP injection alone had no effect on DWB or EPS by day 6. Substance
P signal intensity appeared to be higher in the ipsilateral DRG
compared to the contralateral in arthritic animals. Articular inﬂam-
mation in CAR induced arthritic mice was not prevented by CAP.-
Conclusions: Pain can be quantitated in murine arthritis models using
measures of DWB and EPS. EPS increased and DWB of the affected limb
decreased signiﬁcantly with acute inﬂammatory arthritis. Analgesia
produced by IA MOR was detected by both DWB and EPS in arthritic
mice. Arthritic animals pretreated with capsaicin did not develop pain
as measured by EPS or DWB though there was histologic evidence for
acute inﬂammation. DWB appears to have signiﬁcant utility for
measuring arthritis pain in animal models. It is sensitive to change, has
good reproducibility between mice and is highly correlated with other
measure of arthritis pain in mice.524
ASSESSING THE EFFICACY OF A VISCOSUPPLEMENT COMBINING
HYALURONIC ACID AND SORBITOL (SYNOLIS-VA) IN PATIENTS
WITH HIGH GRADES KNEE OSTEOARTHRITIS FOR WHOM
CORTICOTHERAPY IS CONTRAINDICATED
M. Bausani. Ortopedia e Traumatologia, Siena, Italy
Purpose: Synolis-VA is an innovative viscosupplement (VS) combining
a high concentration (20 mg/ml) of a > 2 MDa Sodium Hyaluronate
(NaHa) from non animal origin with a high concentration of Sorbitol
(40mg/ml), an oxygen free radical (OFR) scavenger. The strong ability of
Sorbitol to scavenge and neutralize OFR has already been proven to
delay the degradation of the NaHA chains. We hypothesis that the
antioxidant effect of Sorbitol allows reduction of the oxidative stress
affecting chondrocytes and synoviocytes and would therefore play
a fast and durable pain relief effect in patients with high grades knee OA
and with no access to corticotherapy.
Methods: 11 patients with high Kellgren-Lawrence grades symptomatic
Knee OA and contraindication for corticotherapy were included in a 26
weeks prospective open pilot study. Treatment regimen consisted of 3
IA injections of 2 ml of Synolis-VA on week apart. Pain and function
measures using walking pain (WP) 5 points Likert scale (0 to 4),
WOMAC A pain (0 to 20) and WOMAC stiffness (0 to 8) scores were
obtained at W0, W1, W2 and W13 and W26.
Results: 10 patients out of the 11 included in the study were diagnosed
with KL grade IV.
At W0 mean WP was at 3.5, WOMAC pain was 15.2 and WOMAC stiff-
ness was 5.4. At W2, one week after the 2nd Synolis VA injection, re-
ported scores were at their lowest for WP at 2.2 (-37%), WOMAC pain at
10.6 (-32%) and WOMAC stiffness at 2.5 (-53%), with 11 responders. 26
weeks after treatment initiation, scores were still signiﬁcantly
improved forWP at 2.5 (-29%), WOMAC pain at 11.8 (-22%) andWOMAC
stiffness at 3.1 (-43%) with 10 responders, demonstrating prolonged
signiﬁcant activity up to 26 weeks.
Conclusions: This study demonstrates a quick and strong pain relief
occurring immediately after the ﬁrst injection of Synolis-VA. Treat-
ment's beneﬁts were still strongly noticeable at the end of follow-up(W26) despite most of patients diagnosed with Kellgren-Lawrence
grade IV (10 out of 11 patients) and despite the absence of cortico-
therapy.
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PARENTERAL ILOPROST IN THE SYMPTOMATIC TREATMENT OF HIP
OSTEOARTHRITIS
A.-T.D. Magbitang, A. Rubio, M. Tee. Univ. of the Philippines, Philippine
Gen. Hosp., Manila, Philippines
Background: Iloprost is a prostacyclin analogue that has been used in
the treatment of symptomatic bone marrow edema of different
aetiology.
Objective: To present a case of bilateral hip osteoarthritis treated with
intravenous iloprost.
Case: A 32-year old Filipino female presented with pain in the lower
back and bilateral hip of two years duration, precipitated by weight-
bearing activities such as prolonged standing and walking long-
distances, and temporarily relieved by rest. She had no known
co-morbid conditions, denied intake of any herbal or over-the-counter
medications, but had a history of practicing mixed-martial arts for eight
years. Complete blood count, blood chemistries and inﬂammatory
markers were all normal. Radiographs of the hips showed sclerosis on
the superior portion of the left acetabulum consistent with osteode-
generative changes. Magnetic resonance imaging of the hips revealed
subtle heterogenous marrow signals within both acetabulum and
femoral heads with minimal effusion. Bone marrow edema, probably of
osteoarthritic etiology was diagnosed. Beginning avascular necrosis was
also considered.
The patient was given Iloprost 20 ug daily intravenous infusions for six
doses. No untoward event was noted. Hip pain decreased by 50% after
the second dose (from VAS 7/10 to VAS 3/10), and completely resolved
after the ﬁfth dose. The patient was subsequently advised off-loading
for 3 to 4 weeks and was prescribed physical therapy for gait training.
Conclusion: Iloprost is a prostacyclin analogue that may be used in the
symptomatic treatment of bone marrow edema of different causes,
including osteoarthritis.
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QUANTITATIVE PROTEOMIC ANALYSIS OF HUMAN BONE MARROW
MESENCHYMAL STEM CELLS SECRETOME DURING
CHONDROGENESIS
B. Rocha y, V. Calamia y, V. Casas z, L. Lourido y, C. Fernández y,
J. Mateos y, P. Fernández-Puente y, M. Carrascal z, F.J. Blanco y, C. Ruiz-
Romero y. yOsteoarticular and Aging Res. Lab., Proteomics Unit-
Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain;
z Laboratorio de Proteómica CSCIC/UAB, Barcelona, Spain
Purpose: A major limited factor for the application of human bone
marrow mesenchymal stem cells (hBMSCs) in cartilage tissue engi-
neering is our understanding of the process by which cartilage is
developed, termed chondrogenesis. This multi-step process is regulated
by a variety of growth factors, including bone morphogenic proteins
and transforming growth factor b (TGF-b) proteins. In addition, chon-
drogenic differentiation is alsomodulated by extracellular matrix (ECM)
proteins. Considering that the functional role for the majority of these
secreted proteins during chondrogenesis process is not fully estab-
lished, we have applied SILAC (Isotope Labeling by Amino Acids in Cell
Culture) technique to analyze the extracellular protein expression
proﬁle of hBMSCs undergoing chondrogenic differentiation.
Methods: hBMSCs isolated from 3 osteoarthritic (OA) patients were
grown in SILAC DMEM with different isotope variants of lysine and
arginine between 4-6 weeks. The fully labelled cell populations were
then subjected to chondrogenesis under a home-made medium con-
taining 10 ng/ml TGF-b3 and other factors for 14 days. 24 h before
collecting the secretome, the micromasses were carefully washed and
